PROGLUMIDE, A CHOLECYSTOKININ RECEPTOR ANTAGONIST, REDUCES NEUROLEPTIC ACTION IN HUNTINGTONS-CHOREA

In a pilot study, proglumide, a cholecystokinin receptor antagonist, w as administered to 8 patients affected from Huntington's chorea under long-term haloperidol treatment. The effectiveness of haloperidol on c hronic symptomatology was reduced by the concomitant administration of proglumide; the latter drug, when administered alone, did not modify the severity of chorea compared to placebo. Possible explanations of t hese results are discussed, stressing the modulatory role of CCK not o nly on the dopaminergic, but also on the GABAergic system.